Kevin Harrington, PhD, FRCR, FRCP - When CPS is Between 1 and 19, How Would You Manage Recurrent/Metastatic SCCHN‪?‬ PeerVoice Clinical Pharmacology Audio

Visit https://www.peervoice.com/JCT860 to view the entire programme with slides. After completing “Kevin Harrington, PhD, FRCR, FRCP - When CPS is Between 1 and 19, How Would You Manage Recurrent/Metastatic SCCHN?”, participants will be able to: Summarise the current treatment guidelines and the importance of combined positive score (CPS) when evaluating first-line systemic treatment options for patients with recurrent/metastatic squamous cell carcinoma of head and neck (SCCHN); Discuss clinical data that help inform treatment plans in patients with recurrent/metastatic SCCHN; and In patients with CPS between 1 and 19, identify patient and disease characteristics that would differentiate patient suitability for a non-immune checkpoint inhibitor (ICI)-based therapeutic regimen versus an ICI-based regimen.